Abstract
In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed alter other chemotherapy. PTT was scheduled by ascalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR+PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.
| Original language | English |
|---|---|
| Pages (from-to) | 123-125 |
| Number of pages | 3 |
| Journal | Cancer Chemotherapy and Pharmacology |
| Volume | 23 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 1989 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Oncology
- Cancer Research
Cite this
Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas. / Tura, S.; Mazza, P.; Gherlinzoni, F.; Zinzani, P. L.; Poletti, G.; Visani, G.; Lemoli, R. M.; Cavo, M.; Galieni, P.; Tassi, C.; Zanchini, R.
In: Cancer Chemotherapy and Pharmacology, Vol. 23, No. 2, 02.1989, p. 123-125.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas
AU - Tura, S.
AU - Mazza, P.
AU - Gherlinzoni, F.
AU - Zinzani, P. L.
AU - Poletti, G.
AU - Visani, G.
AU - Lemoli, R. M.
AU - Cavo, M.
AU - Galieni, P.
AU - Tassi, C.
AU - Zanchini, R.
PY - 1989/2
Y1 - 1989/2
N2 - In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed alter other chemotherapy. PTT was scheduled by ascalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR+PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.
AB - In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed alter other chemotherapy. PTT was scheduled by ascalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR+PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.
UR - http://www.scopus.com/inward/record.url?scp=0024271402&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024271402&partnerID=8YFLogxK
U2 - 10.1007/BF00273532
DO - 10.1007/BF00273532
M3 - Article
C2 - 2910510
AN - SCOPUS:0024271402
VL - 23
SP - 123
EP - 125
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
SN - 0344-5704
IS - 2
ER -